Table 2 Clinical and pathologic features of CRC patients with T2DM examined with immunohistochemistry.

From: Metformin may improve the outcome of patients with colorectal cancer and type 2 diabetes mellitus partly through effects on neutrophil extracellular traps

Ā 

Metformin(ā€“) nā€‰=ā€‰40

Metformin(+) nā€‰=ā€‰40

P

Tumor site (right/left)

18/32

16/34

0.82

Pathology (well/poor)

39/1

39/1

>0.99

pT category (1/2/3/4)

10/5/14/11

7/8/18/7

0.80

pN category (āˆ’/+)

32/8

32/8

>0.99

pStage (I/II/III)

14/18/8

13/19/8

>0.99

Lymphatic invasion (āˆ’/+)

27/23

28/22

>0.99

Venous invasion (āˆ’/+)

11/29

10/30

>0.99

Adjuvant therapy (āˆ’/+)

35/5

33/7

0.76

Back to article page